Borrelia burgdorferi infections in children and adolescents in Switzerland - a seroprevalence study 2023/2024 (BOBUINCA).

Lyme borreliosis Paediatric Seroprevalence Switzerland Tick

Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
26 Sep 2024
Historique:
received: 09 07 2024
accepted: 29 08 2024
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 26 9 2024
Statut: aheadofprint

Résumé

Lyme borreliosis is one of the most prevalent tick-borne diseases in Europe. Studies on seroprevalence of Borrelia burgdorferi IgG antibodies in children are rare. The aim of this study was to determine the seroprevalence of B. burgdorferi IgG antibodies in children and adolescents residing in North-Western Switzerland and neighbouring countries. Prospective cross-sectional observational single-centre study using left-over plasma of asymptomatic paediatric patients. Included were children aged 1-17 years living in North-Western Switzerland and bordering areas of France and Germany. Excluded were children with symptoms of Lyme borreliosis or a chronic disease possibly affecting plasma antibodies (immunodeficiency syndrome, systemic lupus erythematosus) or with such medication (e.g., intravenous immunoglobuline treatment, allogenic stem cell transplantation, immunosuppressive treatment) as well as refugees seeking asylum. IgG antibodies against B. burgdorferi were measured by ELISA and positive or borderline results by line blot. Positivity was defined as scenario 1: ELISA positive/line blot positive or borderline OR ELISA borderline/line blot positive. Scenario 2: ELISA positive or borderline/line blot positive. A multivariable logistic regression model for seropositivity was applied. 962 children were included (mean age 9.63 years, standard deviation 5.01, 54.5% males). Seroprevalence for scenario 1 was 13.3% (95% CI: 11.2-15.6) and for scenario 2 11.2% (95% CI: 9.3-13.4). Seroprevalence (scenario 1) was comparable for age groups, sex and rural versus urban residence. This study shows an increased seroprevalence for B. burgdorferi in the paediatric age compared to previous childhood studies. We also found an increased risk for B. burgdorferi infection at young age.

Sections du résumé

BACKGROUND BACKGROUND
Lyme borreliosis is one of the most prevalent tick-borne diseases in Europe. Studies on seroprevalence of Borrelia burgdorferi IgG antibodies in children are rare. The aim of this study was to determine the seroprevalence of B. burgdorferi IgG antibodies in children and adolescents residing in North-Western Switzerland and neighbouring countries.
METHODS METHODS
Prospective cross-sectional observational single-centre study using left-over plasma of asymptomatic paediatric patients. Included were children aged 1-17 years living in North-Western Switzerland and bordering areas of France and Germany. Excluded were children with symptoms of Lyme borreliosis or a chronic disease possibly affecting plasma antibodies (immunodeficiency syndrome, systemic lupus erythematosus) or with such medication (e.g., intravenous immunoglobuline treatment, allogenic stem cell transplantation, immunosuppressive treatment) as well as refugees seeking asylum. IgG antibodies against B. burgdorferi were measured by ELISA and positive or borderline results by line blot. Positivity was defined as scenario 1: ELISA positive/line blot positive or borderline OR ELISA borderline/line blot positive. Scenario 2: ELISA positive or borderline/line blot positive. A multivariable logistic regression model for seropositivity was applied.
RESULTS RESULTS
962 children were included (mean age 9.63 years, standard deviation 5.01, 54.5% males). Seroprevalence for scenario 1 was 13.3% (95% CI: 11.2-15.6) and for scenario 2 11.2% (95% CI: 9.3-13.4). Seroprevalence (scenario 1) was comparable for age groups, sex and rural versus urban residence.
CONCLUSION CONCLUSIONS
This study shows an increased seroprevalence for B. burgdorferi in the paediatric age compared to previous childhood studies. We also found an increased risk for B. burgdorferi infection at young age.

Identifiants

pubmed: 39325354
doi: 10.1007/s15010-024-02387-7
pii: 10.1007/s15010-024-02387-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet. 2012;379(9814):461–73.
doi: 10.1016/S0140-6736(11)60103-7 pubmed: 21903253
Bahadori A, Ritz N, Zimmermann P. Diagnosis and treatment of Lyme disease in children. Archives Disease Child - Educ Pract Ed. 2023;108(6):422–8.
doi: 10.1136/archdischild-2023-325398
Heininger U, Zimmermann T, Schoerner C, Brade V, Stehr K. [Tick bite and Lyme borreliosis. An epidemiologic study in the Erlangen area]. Monatsschr Kinderheilkd. 1993;141(11):874–7.
pubmed: 8283994
Dong Y, Zhou G, Cao W, Xu X, Zhang Y, Ji Z et al. Global seroprevalence and sociodemographic characteristics of Borrelia burgdorferi sensu lato in human populations: a systematic review and meta-analysis. BMJ Glob Health. 2022;7(6).
van Beek J, Sajanti E, Helve O, Ollgren J, Virtanen MJ, Rissanen H, et al. Population-based Borrelia burgdorferi sensu lato seroprevalence and associated risk factors in Finland. Ticks Tick Borne Dis. 2018;9(2):275–80.
doi: 10.1016/j.ttbdis.2017.10.018 pubmed: 29153461
Hoeve-Bakker BJA, van den Berg OE, Doppenberg HS, van der Klis FRM, van den Wijngaard CC, Kluytmans J et al. Seroprevalence and risk factors of Lyme Borreliosis in the Netherlands: a Population-based cross-sectional study. Microorganisms. 2023;11(4).
Houzvickova A, Dorko E, Rimarova K, Diabelkova J, Drabiscak E. Seroprevalence of Borrelia IgG antibodies among individuals from Eastern Slovakia. Cent Eur J Public Health. 2022;30(Supplement):S16–21.
doi: 10.21101/cejph.a6808 pubmed: 35841220
Skogman BH, Ekerfelt C, Ludvigsson J, Forsberg P. Seroprevalence of Borrelia IgG antibodies among young Swedish children in relation to reported tick bites, symptoms and previous treatment for Lyme borreliosis: a population-based survey. Arch Dis Child. 2010;95(12):1013–6.
doi: 10.1136/adc.2010.183624 pubmed: 20702388
Dehnert M, Fingerle V, Klier C, Talaska T, Schlaud M, Krause G, et al. Seropositivity of Lyme borreliosis and associated risk factors: a population-based study in children and adolescents in Germany (KiGGS). PLoS ONE. 2012;7(8):e41321.
doi: 10.1371/journal.pone.0041321 pubmed: 22905101 pmcid: 3419690
Bohm S, Woudenberg T, Stark K, Bohmer MM, Katz K, Kuhnert R et al. Seroprevalence, seroconversion and seroreversion of Borrelia burgdorferi-specific IgG antibodies in two population-based studies in children and adolescents, Germany, 2003 to 2006 and 2014 to 2017. Euro Surveill. 2023;28(34).
Obaidat MM, Alshehabat MA, Hayajneh WA, Roess AA. Seroprevalence, spatial distribution and risk factors of Borrelia burgdorferi Sensu Lato in Jordan. Comp Immunol Microbiol Infect Dis. 2020;73:101559.
doi: 10.1016/j.cimid.2020.101559 pubmed: 33086189
Geebelen L, Van Cauteren D, Devleesschauwer B, Moreels S, Tersago K, Van Oyen H, et al. Combining primary care surveillance and a meta-analysis to estimate the incidence of the clinical manifestations of Lyme borreliosis in Belgium, 2015–2017. Ticks Tick Borne Dis. 2019;10(3):598–605.
doi: 10.1016/j.ttbdis.2018.12.007 pubmed: 30772196
Bundesamt für Gesundheit BAG AÜK. Zeckenübertragene Krankheiten – Lagebericht Schweiz 2023 [ https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/zeckenuebertragene-krankheiten.html#:~:text=Die%20Borreliose%20(auch%20Lyme%2DKrankheit,migrans%20und%20Borrelien%2DLymphozytom ).
Bundesamt für Landestopografie, swisstopo. Amtliches Ortschaftenverzeichnis n.d. [ https://www.swisstopo.admin.ch/de/geodata/amtliche-verzeichnisse/ortschaftenverzeichnis.html#download
Bundesamt für Statistik (BFS). 01 - Bevölkerung / Bevölkerungsdichte / Gesamtfläche / 2022 Bevölkerungsdichte 2022 2022 [ https://www.atlas.bfs.admin.ch/maps/13/de/17497_75_3501_70/27101.html
Géoclip air. France découverte,. Densité moyenne de population (hab./km²) 2019 [ https://france-decouverte.geoclip.fr/?lang=en#c=indicator&i=pop.dens&s=2019&t=A01&view=map53
Direction Interministérielle du Numérique (DINUM). Base officielle des codes postaux 2023 [ https://www.data.gouv.fr/fr/datasets/base-officielle-des-codes-postaux/
Statistisches Bundesamt. Gemeinden ab 5 000 Einwohnern nach Fläche, Bevölkerung und Bevölkerungsdichte am 31.12.2018 2019 [ https://www.destatis.de/DE/Themen/Laender-Regionen/Regionales/Gemeindeverzeichnis/Administrativ/07-gemeinden.html
Barreiro-Hurlé L, Melón-García S, Seco-Bernal C, Muñoz-Turrillas C, Rodríguez-Pérez M. Seroprevalence of Lyme disease in southwest Asturias. Enfermedades Infecciosas y Microbiol Clin (English ed). 2020;38(4):155–8.
Lledo L, Gegundez MI, Gimenez-Pardo C, Alamo R, Fernandez-Soto P, Nuncio MS, et al. A seventeen-year epidemiological surveillance study of Borrelia burgdorferi infections in two provinces of northern Spain. Int J Environ Res Public Health. 2014;11(2):1661–72.
doi: 10.3390/ijerph110201661 pubmed: 24487455 pmcid: 3945560
BAFU et al. Klimawandel in Der Schweiz. Indikatoren zu Ursachen, Auswirkungen, Massnahmen. Umweltzustand: Bundesamt für Umwelt (BAFU); 2020.
Verloigne M, Van Lippevelde W, Maes L, Yildirim M, Chinapaw M, Manios Y, et al. Levels of physical activity and sedentary time among 10- to 12-year-old boys and girls across 5 European countries using accelerometers: an observational study within the ENERGY-project. Int J Behav Nutr Phys Act. 2012;9:34.
doi: 10.1186/1479-5868-9-34 pubmed: 22462550 pmcid: 3359200
Evison J, Aebi C, Francioli P, Péter O, Bassetti S, Gervaix A et al. Abklärung Und Therapie Der Lyme-Borreliose Bei Erwachsenen Und Kindern. Schweizerische Ärztezeitung. 2005;86(41).

Auteurs

Laura Heeb (L)

Infectious Disease and Vaccinology Unit, University Children's Hospital Basel, University of Basel, Spitalstrasse 33, Basel, CH-4031, Switzerland.

Nora Fritschi (N)

Department of Clinical Research, University of Basel, Basel, Switzerland.
Department of Paediatrics and Paediatric Infectious Diseases, Children's Hospital of Central Switzerland, Lucerne, Switzerland.

Andrea Marten (A)

Infectious Disease and Vaccinology Unit, University Children's Hospital Basel, University of Basel, Spitalstrasse 33, Basel, CH-4031, Switzerland.

Tatjana Welzel (T)

Pediatric Rheumatology, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Pediatric Research Center, University Children's Hospital Basel, University of Basel, Basel, Switzerland.

Nicole Ritz (N)

Infectious Disease and Vaccinology Unit, University Children's Hospital Basel, University of Basel, Spitalstrasse 33, Basel, CH-4031, Switzerland.
Department of Clinical Research, University of Basel, Basel, Switzerland.
Department of Paediatrics and Paediatric Infectious Diseases, Children's Hospital of Central Switzerland, Lucerne, Switzerland.
Department of Paediatrics, The Royal Children's Hospital Melbourne, The University of Melbourne, Melbourne, Australia.

Ulrich Heininger (U)

Infectious Disease and Vaccinology Unit, University Children's Hospital Basel, University of Basel, Spitalstrasse 33, Basel, CH-4031, Switzerland. ulrich.heininger@ukbb.ch.
Department of Clinical Research, University of Basel, Basel, Switzerland. ulrich.heininger@ukbb.ch.

Classifications MeSH